04.26.26 -- Oil Prices, Tariff Volatility, And The FDA Heighten Life Sciences Risks

This weekend’s selections from Life Science Leader analyze the biopharma impacts of key macro issues in the U.S. and globally, from the ongoing conflict in the Middle East to the Trump administration’s pharma tariffs and MFN policy. Oil prices are driving up supplier costs, and Beroe Inc.’s Mathini Ilancheran puts hard numbers on the material increases clinical developers can expect.

On pharma tariffs and the MFN policy, President Trump’s executive order on April 2 converts those policies into enforceable trade law; smart companies should act now to map supplier relationships and reserve U.S. fill/finish capacity, before onshoring commitments add more competition for those capacity slots.

The Business of Biotech podcast welcomed back Allan Shaw for a wide-ranging discussion on FDA politicization and associated risks, and what it means for drug developers and investors.

Check out a curated selection from our partners, below, and thanks for reading.

Ben Comer      
Chief Editor, Life Science Leader

Citeline explains how mandatory UK transparency laws introduce legal, operational, and reputational risk that sponsors must address immediately. (More)

Flourish Research reveals why disconnected innovation increases execution risk unless technology truly integrates into real‑world CNS workflows. (More)

EmVenio Clinical Research examines whether AI can reduce recruitment risk globally without creating new regulatory or access barriers. (More)

Ergomed Clinical Research highlights early oncology trial decisions that quietly lock in safety, regulatory, and credibility risk. (More)

CSS suggests why trust‑based, community recruitment reduces enrollment volatility where digital and site expansion have failed. (More)

Eurofins PSS Insourcing Solutions demonstrates how insourcing and outsourcing models protect timelines and budgets amid restricted headcounts. (More)

Southern Star Research explores how CRO partnerships help biotechs manage operational risk while preserving capital efficiency. (More)